Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
7.41
Dollar change
-0.04
Percentage change
-0.54
%
Index- P/E- EPS (ttm)-83.92 Insider Own49.83% Shs Outstand1.17M Perf Week-9.74%
Market Cap8.67M Forward P/E- EPS next Y- Insider Trans- Shs Float0.59M Perf Month-15.41%
Income-22.01M PEG- EPS next Q- Inst Own19.81% Short Float1.49% Perf Quarter-24.28%
Sales0.80M P/S10.84 EPS this Y- Inst Trans-18.69% Short Ratio0.76 Perf Half Y-52.74%
Book/sh-11.15 P/B- EPS next Y- ROA-394.13% Short Interest0.01M Perf Year-90.95%
Cash/sh0.11 P/C66.69 EPS next 5Y- ROE-1797.63% 52W Range7.16 - 100.80 Perf YTD-20.38%
Dividend Est.- P/FCF- EPS past 5Y23.92% ROI- 52W High-92.65% Beta0.74
Dividend TTM- Quick Ratio0.35 Sales past 5Y-8.43% Gross Margin82.77% 52W Low3.48% ATR (14)0.67
Dividend Ex-Date- Current Ratio0.35 EPS Y/Y TTM21.12% Oper. Margin-2895.09% RSI (14)38.76 Volatility5.79% 6.65%
Employees43 Debt/Eq- Sales Y/Y TTM1490.00% Profit Margin-2768.81% Recom1.00 Target Price1470.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q34.86% Payout- Rel Volume1.52 Prev Close7.45
Sales Surprise- EPS Surprise- Sales Q/Q-60.00% Earnings- Avg Volume11.62K Price7.41
SMA20-9.39% SMA50-13.70% SMA200-73.57% Trades Volume17,648 Change-0.54%
Date Action Analyst Rating Change Price Target Change
Sep-23-20Downgrade BTIG Research Buy → Neutral
Sep-04-18Initiated Ladenburg Thalmann Buy $22
Mar-27-24 08:30AM
Feb-21-24 08:00AM
Feb-15-24 08:00AM
Feb-12-24 11:03AM
Feb-07-24 08:00AM
08:00AM Loading…
Dec-04-23 08:00AM
Nov-13-23 08:00AM
Oct-31-23 09:00AM
Oct-26-23 09:30AM
Oct-06-23 08:08AM
Sep-28-23 09:00PM
08:00AM
Sep-27-23 08:00AM
Sep-26-23 08:00AM
Sep-22-23 04:30PM
08:10AM Loading…
Aug-14-23 08:10AM
Jun-01-23 08:00AM
May-15-23 04:45PM
Apr-25-23 08:00AM
Apr-12-23 08:00AM
Apr-03-23 08:30AM
08:00AM
Mar-23-23 08:00AM
Mar-21-23 08:30AM
Mar-09-23 08:00AM
Jan-26-23 06:06PM
Jan-09-23 08:00AM
Nov-29-22 05:43PM
Nov-28-22 08:00AM
Nov-16-22 05:38AM
08:30AM Loading…
Nov-14-22 08:30AM
Nov-10-22 09:00AM
Nov-03-22 06:16AM
Aug-15-22 08:10AM
Aug-08-22 11:00AM
Jul-29-22 07:00AM
Jul-21-22 08:21AM
May-25-22 08:00AM
May-16-22 08:15AM
Apr-25-22 08:00AM
Mar-31-22 09:15AM
Mar-09-22 09:00AM
Feb-24-22 08:00AM
Feb-11-22 11:24AM
Jan-28-22 07:57AM
Jan-27-22 04:15PM
Jan-26-22 11:18AM
08:00AM
Jan-04-22 08:00AM
Nov-10-21 08:00AM
Nov-09-21 08:00AM
Nov-08-21 08:15AM
Nov-04-21 08:00AM
Nov-01-21 08:00AM
Sep-17-21 08:00AM
Sep-15-21 08:00AM
Aug-16-21 08:15AM
Jul-21-21 07:45AM
Jun-30-21 08:00AM
Jun-08-21 07:57AM
07:00AM
May-19-21 08:00AM
May-17-21 08:15AM
Apr-21-21 08:00AM
Mar-16-21 08:05AM
Mar-11-21 08:00AM
Feb-23-21 07:25AM
Feb-22-21 08:30AM
Feb-19-21 12:20PM
10:36AM
07:30AM
Jan-07-21 08:19AM
Jan-06-21 08:43AM
Jan-05-21 08:00AM
Nov-13-20 08:05AM
Oct-29-20 11:15AM
Oct-26-20 07:55AM
Oct-12-20 08:53AM
Sep-23-20 10:34AM
Sep-22-20 08:40AM
07:30AM
Sep-17-20 08:00AM
Aug-27-20 08:00AM
Aug-14-20 09:45AM
08:30AM
Aug-05-20 12:30PM
Jul-16-20 11:30AM
Jul-07-20 08:37AM
07:55AM
Jun-09-20 08:00AM
May-14-20 10:05AM
08:45AM
May-13-20 05:02PM
12:30PM
Apr-27-20 07:45AM
Apr-07-20 07:55AM
Mar-31-20 07:55AM
Mar-09-20 07:46AM
Feb-06-20 07:31AM
Dec-10-19 08:02AM
Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington's disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in April 2001 and is headquartered in Rochester, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Van Strydonck, Gerald E.DirectorDec 26 '23Sale0.723,1492,2670Dec 28 04:31 PM
Van Strydonck, Gerald E.DirectorDec 08 '23Sale0.671,3348943,149Dec 12 04:31 PM
Zauderer MauricePresident and CEOOct 04 '23Buy0.975,0004,86522,116Oct 05 04:31 PM
FRIEDBERG ALBERTDirectorOct 03 '23Buy1.003,000,0003,000,0004,747,794Oct 05 04:30 PM
Zauderer MauricePresident and CEOOct 03 '23Buy1.00500,000500,000979,599Oct 05 04:31 PM
Zauderer MauricePresident and CEOOct 03 '23Buy0.935,0004,65017,116Oct 05 04:31 PM